Bleeding Risk During Treatment of Acute Thrombotic Events with Subcutaneous LMWH Compared to Intravenous Unfractionated Heparin; a Systematic Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Sep 18

PMID 22984525

Citations 7

Authors

Giorgio Costantino

Elisa Ceriani

Anna Maria Rusconi

Gian Marco Podda

Nicola Montano

Piergiorgio Duca

Marco Cattaneo

Giovanni Casazza

Affiliations

Soon will be listed here.

Abstract

Background: Low Molecular Weight Heparins (LMWH) are at least as effective antithrombotic drugs as Unfractionated Heparin (UFH). However, it is still unclear whether the safety profiles of LMWH and UFH differ. We performed a systematic review to compare the bleeding risk of fixed dose subcutaneous LMWH and adjusted dose UFH for treatment of venous thromboembolism (VTE) or acute coronary syndromes (ACS). Major bleeding was the primary end point.

Methods: Electronic databases (MEDLINE, EMBASE, and the Cochrane Library) were searched up to May 2010 with no language restrictions. Randomized controlled trials in which subcutaneous LMWH were compared to intravenous UFH for the treatment of acute thrombotic events were selected. Two reviewers independently screened studies and extracted data on study design, study quality, incidence of major bleeding, patients' characteristics, type, dose and number of daily administrations of LMWH, co-treatments, study end points and efficacy outcome. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated using the random effects model.

Results: Twenty-seven studies were included. A total of 14,002 patients received UFH and 14,635 patients LMWH. Overall, no difference in major bleeding was observed between LMWH patients and UFH (OR = 0.79, 95% CI 0.60-1.04). In patients with VTE LMWH appeared safer than UFH, (OR = 0.68, 95% CI 0.47-1.00).

Conclusion: The results of our systematic review suggest that the use of LMWH in the treatment of VTE might be associated with a reduction in major bleeding compared with UFH. The choice of which heparin to use to minimize bleeding risk must be based on the single patient, taking into account the bleeding profile of different heparins in different settings.

Citing Articles

Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism-From Modern Recommendations to Clinical Application.

Lasica R, Asanin M, Djukanovic L, Radovanovic N, Savic L, Polovina M Pharmaceuticals (Basel). 2022; 15(9).

PMID: 36145366 PMC: 9501350. DOI: 10.3390/ph15091146.

Pharmacists as members of an interdisciplinary pulmonary embolism response team.

Groth C, Acquisto N, Wright C, Marinescu M, McNitt S, Goldenberg I J Am Coll Clin Pharm. 2022; 5(4):390-397.

PMID: 35813573 PMC: 9269076. DOI: 10.1002/jac5.1569.

Pharmacokinetic, Hemostatic, and Anticancer Properties of a Low-Anticoagulant Bovine Heparin.

Santos R, Tovar A, Oliveira M, Piquet A, Capille N, Oliveira S TH Open. 2022; 6(2):e114-e123.

PMID: 35707626 PMC: 9135479. DOI: 10.1055/s-0042-1745743.

Low-molecular-weight heparin and intermittent pneumatic compression for thromboprophylaxis in critical patients.

Wan B, Fu H, Yin J, Ren G Exp Ther Med. 2015; 10(6):2331-2336.

PMID: 26668637 PMC: 4665354. DOI: 10.3892/etm.2015.2795.

Postoperative Acute Pulmonary Embolism Following Pulmonary Resections.

Shonyela F, Yang S, Liu B, Jiao J Ann Thorac Cardiovasc Surg. 2015; 21(5):409-17.

PMID: 26354232 PMC: 4904848. DOI: 10.5761/atcs.ra.15-00157.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Antman E, Morrow D, McCabe C, Jiang F, White H, Fox K . Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction.... Am Heart J. 2005; 149(2):217-26. DOI: 10.1016/j.ahj.2004.08.038. View

. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study. Indian Heart J. 2006; 57(6):648-54. View

Aiach M, Fiessinger J, Vitoux J, Derlon A, Grollier G, Le Querrec A . [Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study]. Rev Med Interne. 1989; 10(4):375-81. View

Harenberg J, Schmidt J, Koppenhagen K, Tolle A, Huisman M, Buller H . Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thromb Haemost. 2000; 83(5):652-6. View

Hull R, Raskob G, Pineo G, Green D, Trowbridge A, Elliott C . Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992; 326(15):975-82. DOI: 10.1056/NEJM199204093261502. View

Stricker H, Marchetti O, Haeberli A, Mombelli G . Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thromb Haemost. 1999; 82(4):1227-31. View

Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J, Azarian R . A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997; 337(10):663-9. DOI: 10.1056/NEJM199709043371002. View

Campos J, Juarez Herrera U, Rosas Peralta M, Lupi Herrera E, Pacheco H, Martinez Sanchez C . [Decrease of total hemorrhage with reduced doses of enoxaparin in high risk unstable angina. ENHNFAI study. (Enoxaparin vs non-fractionated heparin in unstable angina). Preliminary report]. Arch Cardiol Mex. 2002; 72(3):209-19. View

10.

Zhang Y, Wang X, Yang C, Liu G . [Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction]. Di Yi Jun Yi Da Xue Xue Bao. 2004; 24(1):81-4. View

11.

Magee K, Sevcik W, Moher D, Rowe B . Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst Rev. 2003; (1):CD002132. DOI: 10.1002/14651858.CD002132. View

12.

Manoukian S, Feit F, Mehran R, Voeltz M, Ebrahimi R, Hamon M . Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007; 49(12):1362-8. DOI: 10.1016/j.jacc.2007.02.027. View

13.

Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B . Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost. 1995; 74(6):1432-5. View

14.

Perez de Llano L, Baloira Villar A, Veres Racamonde A, Veiga F, Golpe Gomez R, Pajuelo Fernandez F . [Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism]. Arch Bronconeumol. 2003; 39(8):341-5. DOI: 10.1016/s0300-2896(03)75401-5. View

15.

Goodman S, Fitchett D, Armstrong P, Tan M, Langer A . Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107(2):238-44. DOI: 10.1161/01.cir.0000050144.67910.13. View

16.

Cohen M, Theroux P, Borzak S, Frey M, White H, Van Mieghem W . Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using.... Am Heart J. 2002; 144(3):470-7. DOI: 10.1067/mhj.2002.126115. View

17.

Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle C, Mall K . Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis. 1990; 20 Suppl 1:205-19. DOI: 10.1159/000216179. View

18.

Harrington R, Becker R, Cannon C, Gutterman D, Lincoff A, Popma J . Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):670S-707S. DOI: 10.1378/chest.08-0691. View

19.

Fiessinger J, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson C . Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996; 76(2):195-9. View

20.

Prandoni P, Lensing A, Buller H, Carta M, Cogo A, Vigo M . Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339(8791):441-5. DOI: 10.1016/0140-6736(92)91054-c. View